ClinicalTrials.gg
CompletedNCT01164124PASUpdated Jul 2, 2018

Probiotics-Supplemented Feeding in Extremely Low Birth Weight Infants

A Phase 2/3 interventional study of Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis) and Placebo in Low Birth Weight, sponsored by Vermont Oxford Network. Completed at 3 sites in United States. Open to participants aged 1 Day to 14 Days. Per ClinicalTrials.gov, last updated 2018-07-02.

Sponsored by Vermont Oxford Network · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
1 Day to 14 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 742 studies in Premature Birth with a site in United States — 103 open to participants now, 136 under way, 9 of them phase 3. Premature Birth · United States.

Enrollment
228th of 529
101 · median 85
Started
2008
with 31 others
Phase 2/3
17 of 742
2 open now
Registered
185th of 742
by date

Among the 742 studies in Premature Birth with a site in United States, this one is the 228th largest by enrollment of the 529 interventional ones that give a count, is one of 32 that started in 2008, is one of 17 in phase 2/3, and was the 185th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

103 of the 742 studies in Premature Birth with a site in United States are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 1 Day to 14 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 742 studies in Premature Birth with a site in United States, or all of them as a file.
02

Study summary

The overall purpose of this research is to test whether adding a supplement to the feeding of extremely low birth weight infant (infants weighing less than 2 pound 2 oz at birth) will help him/her achieve full feeding faster and achieve better weight gain.

Read the detailed description

The overall purpose of this research is to test whether adding a supplement to the feeding of extremely low birth weight infant (infants weighing less than 2 pound 2 oz at birth) will help him/her achieve full feeding faster and achieve better weight gain. The study also will evaluate the benefit of that feeding supplement in decreasing the rate of infection (in the blood or in the urine) and antibiotics use in those infants.

When babies are born, the digestive system (the gastrointestinal tract) is sterile. There are no bacteria residing in their gut. When babies start feeding, it is normal for the intestine to start growing several types of bacteria. These normal (good) bacteria are thought to be helpful in keeping the intestine healthy. This is not the case in premature infants. It takes premature infants a longer time to grow bacteria in their intestines and they have fewer numbers of bacteria. In addition, the bacteria premature infants grow are not the normal one that we see in healthy infants. Instead they grow unhealthy (bad) bacteria that can potentially play a role in causing infection in the blood and urine.

Adding the normal (good) bacteria to the breast milk or infant formula might help to protect premature babies from developing blood or urine infection. In addition, adding the good bacteria might be beneficial in terms of better tolerance to milk feeding. As a result, babies may have less episodes of feeding holding and have better weight gain. Two species of bacteria, called Lactobacillus and Bifidobacteria, have been used to study this in other studies of premature babies. These two species are the most plentiful bacteria seen in the bowels of full term babies.

Participation in the study involves enrolling premature babies to receive supplement to the feeding when he/she ready to feed. Babies will be randomly assigned to receive either a bacteria (probiotic) supplement or be fed without supplement. The supplement will be added to one feeding each day. Enrolled babies will continue to get the supplement for 6-10 week. Other than the feeding supplement, being in this study will not affect care.

The main outcomes of the study will be feeding tolerance and growth. Other complications associated with prematurity, on particular infection of either the gastrointestinal tract or the blood stream will be evaluated.

03

Conditions studied

  • Low Birth Weight

Browse trials for

Keywords

  • extremely low birth weight
  • probiotics
  • growth
  • nutrition
  • premature infants
  • growth in extremely low birth weight infants
04

Who can participate

Ages eligible
1 Day to 14 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • birth weight less than or equal to 1000 grams,
  • appropriately grown for gestational age,
  • age 1 to 14 days inclusive,
  • intention to start enteral feeds,
  • written obtained

Exclusion criteria

Exclusion Criteria:

  • known life-threatening congenital anomaly or condition affecting
  • gastrointestinal function,
  • previous NEC or gastrointestinal perforation,
  • previous supplementation with probiotics
  • previous enteral feedings
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Probiotic supplementation

    500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter \& Gamble.Inc)

    Dietary Supplement: Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)

  • Placebo comparator
    Routine feedings

    Other: Placebo

Interventions

  • Dietary supplementProbiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)

    The probiotic regimen consisted of 500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter \& Gamble.Inc)

  • OtherPlacebo

    routine feedings

06

What researchers measure

Primary outcomes

  1. Growth

    Percentage of infants with weight less than the 10th percentile at 34 weeks postmenstrual age.

    Time frame: 34 weeks postmenstrual age

  2. Growth

    Average weight gain and growth velocity during the first 28 days from initiation of feeding.

    Time frame: 28 days from study entry

  3. Feeding Tolerance

    Volume of feeding per day during the first 28 days from the initiation of feeding.

    Time frame: 28 days from study entry

Secondary outcomes

  1. Antimicrobial therapy

    Days of antimicrobial treatment until 34 weeks post menstrual age.

    Time frame: 34 weeks post menstrual age

  2. Complications of prematurity

    common complications of prematurity including but not limited to sepsis, necrotizing enterocolitis, and mortality.

    Time frame: until hospital discharge

07

Study locations

3 sites
  • St. John Hospital & Medical Center
    Detroit, Michigan 48236, United States
  • Cardinal Glennon Children's Hospital
    Saint Louis, Missouri 63104-1095, United States
  • VT Children's at Fletcher-Allen Health Care
    Burlington, Vermont 05401, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of May 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2010
First posted
Jul 16, 2010
Start
Feb 2008
Primary completionActual
May 2009
CompletionActual
Aug 2009
Last update
Jul 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01164124
Lead sponsor
Vermont Oxford Network
Collaborators
University of Vermont, St. Louis University, Cardinal Glennon Children's Hospital, Saint John Hospital & Medical Center
Responsible party
Sponsor
First posted
Jul 16, 2010
Start date
Feb 2008
Primary completion
May 2009
Completion
Aug 2009
Last update
Jul 2, 2018

Study contacts

Mohamad Al-Hosni, MD
principal investigator · St. Louis University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion